Phase III ARTEMIS-008 Trial Shows Risvutatug Rezetecan Significantly Improves Overall Survival in Relapsed Small-Cell Lung Cancer
Phase 3positiverisvutatug rezetecanPositive
AI Analysis
Summary
Phase III ARTEMIS-008 trial of risvutatug rezetecan, a B7-H3-directed antibody-drug conjugate, demonstrates a 54% reduction in death risk versus topotecan in relapsed small-cell lung cancer, with improved progression-free survival and response rates.
Clinical Trial Data
Phase
III
Primary Endpoint
Met
Outcome Details
54% reduction in risk of death compared to topotecan; improved progression-free survival and response rates
Importance:8/10
Sentiment:
0.85
oncologysmall-cell lung cancerantibody-drug conjugateB7-H3Phase 3overall survival
Read the original article
Published by PR Newswire Pharma on September 13, 2026 11:46 AM